High Prevalence of the K65R Mutation in Human Immunodeficiency Virus Type 1 Subtype C Isolates from Infected Patients in Botswana Treated with Didanosine-Based Regimens-Reference-Cited by-同舟云学术

High Prevalence of the K65R Mutation in Human Immunodeficiency Virus Type 1 Subtype C Isolates from Infected Patients in Botswana Treated with Didanosine-Based Regimens

Published:2006-12 Issue:12 Volume:50 Page:4182-4185
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Doualla-Bell Florence¹²,Avalos Ava³,Brenner Bluma²,Gaolathe Tendani¹³,Mine Madisa¹,Gaseitsiwe Simani¹,Oliveira Maureen²,Moisi Daniella²,Ndwapi Ndwapi¹,Moffat Howard³,Essex Max¹⁴,Wainberg Mark A.²

Affiliation:

1. Botswana-Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education, Gaborone, Botswana

2. McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada

3. Infectious Disease Care Clinic, Princess Marina Hospital, Gaborone, Botswana

4. Harvard School of Public Health, Boston, Massachusetts

Abstract

ABSTRACT We analyzed the reverse transcriptase genotypes of human immunodeficiency virus type 1 subtype C viruses isolated from 23 patients in Botswana treated with didanosine-based regimens. The K65R mutation was selected either alone or together with the Q151M, S68G, or F116Y substitution in viruses from seven such individuals. The results of in vitro passage experiments were consistent with an apparent increased propensity of subtype C viruses to develop the K65R substitution.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00714-06

Reference18 articles.

1. Abecasis, A. B., K. Deforche, J. Snoeck, L. T. Bacheler, P. McKenna, A. P. Carvalho, P. Gomes, R. J. Camacho, and A. M. Vandamme. 2005. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS19:1799-1806.

2. Brenner, B., M. Oliveira, F. Doualla-Bell, D. Moisi, M. Ntemgwa, F. Frankel, M. Essex, and M. A. Wainberg. 2006. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS20:F9-F13.

3. Brenner, B., D. Turner, M. Oliveira, D. Moisi, M. Detorio, M. Carobene, R. G. Marlink, J. Schapiro, M. Roger, and M. A. Wainberg. 2003. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS17:F1-F5.

4. Chaix, M. L., D. Descamps, M. Harzic, V. Schneider, C. Deveau, C. Tamalet, I. Pellegrin, J. Izopet, A. Ruffault, B. Masquelier, L. Meyer, C. Rouzioux, F. Brun-Vezinet, and D. Costagliola. 2003. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS17:2635-2643.

5. Doualla-Bell, F., S. Gaseitsiwe, T. Ndungu, M. Modukanele, T. Peter, V. A. Novitsky, N. Ndwapi, G. Tendani, A. Avalos, W. Wester, H. Bussmann, P. Cardiello, R. Marlink, H. Moffat, I. Thior, M. A. Wainberg, and M. Essex. 2004. Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients. Antivir. Chem. Chemother.15:189-200.

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes;Viruses;2023-09-25

2. HIV-1 resistance to islatravir/tenofovir combination therapy in wild-type or NRTI resistant strains of diverse HIV-1 subtypes;2023-06-18

3. The S68G polymorphism is a compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE strains;BMC Infectious Diseases;2020-02-11

4. Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase;Pharmaceuticals;2019-04-20

5. QSAR based therapeutic management of M. tuberculosis;Archives of Pharmacal Research;2017-04-29